I Put Twelve GLP-1 Trials on One Page

The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.

SPECIAL EDITION: Nobody Asked.

A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.

I Built a Live Index of Every Obesity Drug Trial

The pipeline moves faster than any newsletter can. So I stopped trying to summarize it and built something that updates itself.

Obesity Medicine Stopped Being a Horse Race

Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.

The patient barely lost weight. He got better anyway.

What the newest trial data reveal about GLP-1 medicines, and why "weight loss drug" may be the least interesting thing about them.

Medicare Will Pay for Wegovy Now. Here's the Catch.

Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.

Glucagon Doesn't Win the Scale. It Wins the Liver.

Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.

GLP-1 Resistance Is Real. You Probably Don’t Have It.

A genetic study just caught true GLP-1 resistance in the act. Almost no one being called a “non-responder” fits the description.

The Side Effect Toolbox: How to Keep Patients On the Drug

Most patients don't fail GLP-1 therapy because the drug doesn't work. They fail because nobody managed the nausea — and we let them walk away from a treatment that was working.

The Accidental Hormone.

A century-long hunt for a phantom gut hormone, a peptide chemist written out of the story, and a venomous desert lizard. Here is where Ozempic actually comes from — and who actually found it.

ECO 2026: The Maintenance Era Begins.

Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.

How Much Muscle Are GLP-1 Patients Actually Losing?

Two systematic reviews. One question. Different answers.

Before or After? The GLP-1 and Surgery Sequencing Question

The science of sequencing GLP-1 therapy and bariatric surgery — and why the answer is more complicated than anyone wants to admit.

The Longevity Stack

Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.

What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight

It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.

Cleared for Takeoff

The Definitive GLP-1 Travel Guide — TSA, Storage, Dosing, and Everything In Between

SPECIAL EDITION: When the Drug Stops Working (Because You Stopped the Drug)

A new BMJ Medicine analysis quantifies what happens to cardiovascular risk after GLP-1 discontinuation. The numbers are striking. The framing some are applying to them is wrong.

The Drug That May Redefine What's Possible

Retatrutide may be the first pharmacotherapy to approach bariatric surgery–level weight loss. Phase 3 data now confirm what phase 2 only suggested: this is a categorically different molecule.

SPECIAL EDITION: I've Been Taking Low-Dose Tirzepatide for Two Years. Here's What I've Learned.

A physician's honest account of off-label self-experimentation — and why I don't recommend you follow my lead.

Why Weight Returns After Stopping GLP-1 Therapy: The Biology You Need to Understand

Across randomized trials, stopping GLP-1/dual incretin therapy is typically followed by clinically meaningful weight regain and loss of cardiometabolic gains—often within months—highlighting obesity as a chronic, relapsing condition.

Why Obesity Is Not a Choice

The neuroscience and evolutionary biology behind a widely misunderstood disease

The GLP1 Problem